

ASX ANNOUNCEMENT

Release of Shares from Voluntary Escrow

* * * * * *

MELBOURNE, Australia (23 August 2021): Lumos Diagnostics Holdings Limited (ASX: LDX, 'Lumos' or the 'Company') advises that, in accordance with ASX Listing Rule 3.10A and as stated in the Prospectus dated 7 June 2021, 9,836,317 fully paid ordinary shares will be released from voluntary escrow on 30 August 2021 upon the release of the Company's FY21 Results.

These shares are already quoted on ASX.

This announcement is authorised for release to the market by the Lumos Company Secretary.

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information on Lumos Diagnostics, visit <u>lumosdiagnostics.com</u>, and for more information on FebriDx, visit <u>febridx.com</u>.

Investor Contact:

Matthijs Smith – Lumos Diagnostics ir@lumosdiagnostics.com +61 411 137 080 +61 3 9087 1598

Media Contact (Australia):

Haley Chartres – H^CK haley@hck.digital +61 423 139 163

Media Contacts (U.S. and Global):

Jennifer Christiansen – Lumos Diagnostics communications@lumosdiagnostics.com +1 920 784 3153 +1 941 928 9025

Company Registered Office:

Lumos Diagnostics Holdings Ltd Level 4, 100 Albert Rd South Melbourne, VIC 3205 +61 3 9087 1598